Investor Relations

On these pages you will find the articles and by-laws of the company as well as current information regarding Sangui share price.

In order to facilitate information processes for our shareholders the frequently asked questions section ("FAQ") will not only contain basic information but will also be updated on a regular basis.

Please refer to our Corporate Presentation for more details about the status of our wound management activities,

Please note, that Sangui continues to be a high risk investment. Investors should be aware of the risk sections included in our recent SEC filings. Comprehensive risk information is contained in the risk memorandum avalailable for download here.

Sangui BioTech International, Inc. wants to point out that there is no broker nor any other person or institution mandated or authorized by Sangui to purchase or sell shares of the company. There are currently no warrants, options or other derivatives based on Sangui shares outstanding which are authorized by the company.

No. of Sangui shares issued and outstanding: approx. 120 million

No. of Sangui shares authorized: 250,000,000 common stock, 10,000,000 preferred stock

Cusip No.: 80105B101 ISIN: US80105B1017

Traded: www.otcmarkets.com (symbol: SGBI)

WKN: 906757

Traded: OTC market in Hamburg (Symbol: SBH)